The IMPDH1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Jurkat T lymphoblastoid cell line, engineered for loss-of-function studies of inosine monophosphate dehydrogenase 1 (IMPDH1). This product consists of a heterogeneous polyclonal pool of cells harboring targeted disruptions in the IMPDH1 gene, enabling robust investigation of IMPDH1-dependent pathways in a T cell context. As a polyclonal knockout model, it reflects the genetic variability inherent in CRISPR/Cas9-mediated gene editing, providing a powerful resource for studying gene function without clonal selection artifacts.
The parental Jurkat cell line is an immortalized human T lymphocyte line originally established from the peripheral blood of a patient with acute T cell leukemia. Jurkat cells serve as a classical model system for dissecting T cell receptor (TCR) signaling, cytokine production, and apoptosis, and they are extensively employed in cancer research to study mechanisms of leukemogenesis and lymphoproliferation. Their rapid growth and ease of genetic manipulation make them particularly amenable to CRISPR/Cas9-based gene disruption.
IMPDH1 encodes the enzyme that catalyzes the rate-limiting step in de novo guanine nucleotide biosynthesis: the NAD+-dependent oxidation of inosine monophosphate (IMP) to xanthosine monophosphate (XMP), a critical precursor for guanosine monophosphate (GMP), guanosine diphosphate (GDP), and guanosine triphosphate (GTP). This reaction is essential for maintaining intracellular guanine nucleotide pools required for DNA replication and cell cycle progression. IMPDH1 activity is regulated by the c-Myc transcription factor and mTOR signaling, and it is potently inhibited by the immunosuppressive drug mycophenolic acid. IMPDH1 interacts with IMPDH2 and CTP synthase (CTPS) to coordinate nucleotide metabolism. In T lymphocytes, IMPDH1-mediated guanine nucleotide synthesis is particularly crucial for supporting proliferative responses upon activation, and its pharmacological inhibition leads to reduced lymphocyte proliferation.
In the Jurkat T lymphoblastoid background, disruption of IMPDH1 offers a uniquely relevant model to investigate the dependency of leukemic T cells on de novo guanine nucleotide synthesis and to screen for immunosuppressive or anticancer agents that target this pathway. Given the central role of IMPDH1 in nucleotide metabolism, this knockout population can be employed to dissect the metabolic vulnerabilities of cancer cells and to elucidate the compensatory mechanisms activated upon guanine nucleotide depletion. Furthermore, because IMPDH1 mutations are linked to autosomal dominant retinitis pigmentosa 10 (RP10), these cells provide an accessible cellular platform to study IMPDH1-related pathophysiology, albeit in a non-retinal context.
Researchers can utilize this IMPDH1 knockout polyclonal cell population in a variety of experimental contexts, including screening of IMPDH inhibitors such as mycophenolic acid derivatives, assessing intracellular GTP pools via HPLC or mass spectrometry, and evaluating cell cycle progression and apoptosis upon nucleotide deprivation. The model is well-suited for drug sensitivity assays, Western blot analysis of downstream signaling effects, and functional complementation studies to validate IMPDH1-specific phenotypes. These cells are also valuable for exploring the role of purine metabolism in T cell activation and leukemia cell survival. For detailed protocols, validation data, or technical consultation, please contact Ascent Research.
